CXCL1 and chronic obstructive pulmonary disease: Increasing concentrations (0.1 to 10 μg/mL) of our anti-human GRO-α monoclonal antibody had no effect on EBC neutrophil chemotactic activity of exacerbated COPD patients (n = 10) (data not shown).